Japan Tobacco Inc.

Satoru Kobayashi

Hisashi Shinkai

Hironobu Nagamori

Takahisa Motomura

Koichi Suzawa

Hirotsugu Ito

Toru Morita

Susumu Miyazaki

Wataru Watanabe

Yuji Matsuzaki

Shuichi Wamaki

Susumu Katoh

Hirotaka Isoshima

Kazunobu Yamataka

Kaoru Adachi

Shinichi Kiyonari

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

Fluorene compound and pharmaceutical use thereof

The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor

Growing community of inventors

Takatsuki, Japan

Satoru Kobayashi